Lyllana Patch, Extended Release
FDA Label NDC 65162-150

51 label sections · Submitted to the FDA by Amneal Pharmaceuticals Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Amneal Pharmaceuticals Llc for the product Lyllana (NDC 65162-150). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: endometrial cancer, cardiovascular disorders, probable dementia, and breast cancer, 1 indications and usage, 1.2 prevention of postmenopausal osteoporosis, 2 dosage and administration, 2.1  treatment of moderate to severe vasomotor symptoms due to menopause, 2.3 application instructions, 3 dosage forms and strengths, 4 contraindications, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.